Drug Profile
Research programme: immunosuppressive therapeutics - Amgen
Latest Information Update: 21 Mar 2007
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Immunosuppression; Transplant rejection
Most Recent Events
- 21 Mar 2007 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
- 21 Mar 2007 Discontinued - Preclinical for Immunosuppression in USA (PO)
- 21 Mar 2007 Discontinued - Preclinical for Transplant rejection in USA (PO)